Expert oncologists consider how RET inhibitors will be used in clinical practice: when to implement it in the treatment timeline, whether to sequence with multikinase inhibitors, and the factors that go into making these decisions.
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.
Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.
Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.
The 2025 American Cancer Society Annual Report Showed incidence rates are increasing for many cancer types and disparities remain regarding cancer mortality.
Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program, was recently honored with the American Association for Cancer Research’s NextGen Stars…
Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.
Tagitanlimab received marketing authorization from the Chinese NMPA for use with cisplatin and gemcitabine for patients with recurrent or metastatic NPC.
